Table 1.

Components of comprehensive long-term follow-up of AYA leukemia survivors

Organ system or patient-centered care category	Specific toxicities or outcomes that impact survival, health, or quality of life
Overall survival	Premature mortality
	Cancer recurrence or SN
Cardiac	Cardiomyopathy
Cardiometabolic	Obesity
	Dyslipidemia
	Hypertension
	Insulin resistance, diabetes
Endocrine/gonadal	Anterior pituitary hormone deficiencies in GH, FSH, LH, ACTH, TSH
	Ovarian dysfunction, estrogen and progesterone deficiency
	Testicular dysfunction, oligospermia or azoospermia, testosterone deficiency, germinal epithelium damage, Leydig cell dysfunction
Reproductive	Infertility
	Sexual dysfunction
Musculoskeletal	ON
	Osteopenia/osteoporosis
	Sarcopenia with increased adiposity
Health behaviors	Risky behaviors (smoking, alcohol, sexual behavior)
	Diet and exercise
Health care needs	Chronic health conditions
	Demands of routine surveillance
	Nonadherence to medication and screening
	Lack of information
	Access to care
	Health fears leading to over- or undertreatment
Emotional adjustment	Living with uncertainty, fear of recurrence
	Infertility impacts
	Sexual dysfunction impacting relationships and self-perception
	Body image with self-consciousness
	Hypervigilance
	Posttraumatic stress
	Distress, anxiety, depression
	Suicidal ideation
	Sense of personal growth
Social relationships	Family difficulties: parents, spouse, children
	Peers comparison or separation
	Dating, intimacy
	Decreased social and leisure activities
	Isolation with decreased social support
	Need for multiple health care provider relationships
Functional needs/symptoms	Managing physical limitations
	Fatigue
	Cognitive dysfunction
	Sexual function symptoms
	Insomnia
Employment/finances	Education completion
	Career advancement
	Debt and financial stress
	Insurance coverage

ACTH, adrenocorticotrophic hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; TSH, thyroid-stimulating hormone.